![]() ![]() Pegcetacoplan has been shown to slow or stop the progression of GA, preserving vision for individuals with progressive dry AMD. The progression of macular degeneration into GA and late-stage retinal atrophy can lead to partial or full vision loss without adequate treatment. Through engagement in the clinical study process, the Mid Atlantic Retina team helped prove the efficacy, safety, and tolerability of pegcetacoplan - an effort that ultimately led to FDA approval. The physicians at Mid Atlantic Retina played an integral part in developing this drug over a five-year period when it was tested on a broad range of patients with GA. "FDA approval of our first-ever therapy to slow the progression of geographic atrophy allows us to help patients who otherwise often have a relentlessly progressive form of AMD that can be visually debilitating as time goes on," - lead investigators Allen Chiang, MD, Mitchell S. With clinical study support leading up to the historic approval of pegcetacoplan, the specialists at Mid Atlantic Retina - part of the larger Will Eye Hospital team - continue demonstrating their commitment to ensuring individuals have access to the most advanced, effective treatments available. This includes involvement in clinical research programs investigating advances in surgical techniques, procedures, and pharmaceuticals. FDA approval of intravitreal pegcetacoplan came after three phases of clinical trials conducted over a 24-month period, with direct involvement by Mid Atlantic Retina (and Wills Eye Hospital) physicians during the phase 2 and crucial stage 3 clinical trial periods.Īs a Center for Excellence in treating retinal diseases, Mid Atlantic Retina provides patients with the latest in cutting-edge treatments and techniques for various retinal conditions. Food and Drug Administration (FDA), a groundbreaking new treatment for dry age-related macular degeneration (dry AMD) with geographic atrophy (GA). Physicians at Mid Atlantic Retina are proud to announce the approval of pegcetacoplan by the U.S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |